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Various tumors develop addiction to glutamine to support
uncontrolled cell proliferation. Here we identify the
nuclear receptor liver receptor homolog 1 (LRH-1) as a
key regulator in the process of hepatic tumorigenesis
through the coordination of a noncanonical glutamine
pathway that is reliant on themitochondrial and cytosolic
transaminases glutamate pyruvate transaminase 2 (GPT2)
and glutamate oxaloacetate transaminase 1 (GOT1),
which fuel anabolic metabolism. In particular, we show
that gain and loss of function of hepatic LRH-1 modulate
the expression and activity of mitochondrial glutaminase
2 (GLS2), the first and rate-limiting step of this pathway.
Acute and chronic deletion of hepatic LRH-1 blunts the
deamination of glutamine and reduces glutamine-depen-
dent anaplerosis. The robust reduction in glutaminolysis
and the limiting availability of α-ketoglutarate in turn in-
hibit mTORC1 signaling to eventually block cell growth
and proliferation. Collectively, these studies highlight
the importance of LRH-1 in coordinating glutamine-
induced metabolism and signaling to promote hepatocel-
lular carcinogenesis.
Supplemental material is available for this article.
Received January 7, 2016; revised version acceptedMay 12, 2016.
During tumorigenesis, cancer cells usually switch from
oxidativemetabolism to a highly glycolyticmetabolic sta-
tus (Vander Heiden et al. 2009). While glucose is predom-
inantly metabolized into lactate rather than entering the
tricarboxylic acid (TCA) cycle, cancer cells particularly
rely on glutamine to replenish TCA cycle intermediates.
This process, termed anaplerosis, is accomplished
through the conversion of glutamine to α-ketoglutarate
(α-KG) via a two-step deamination reaction catalyzed by
glutaminases and then by glutamate dehydrogenase 1
(GLUD1) or transaminases (DeBerardinis et al. 2008;
Wise et al. 2008; Csibi et al. 2013; Son et al. 2013). Cancer
cells therefore critically depend on glutamine as a fuel for
proliferation, and abrogation of glutamine metabolism
blocks tumorigenesis, indicating an accessible therapeu-
tic window for cancer treatment (Hensley et al. 2013).
Liver receptor homolog 1 (LRH-1; also called NR5A2) is
a nuclear receptor that is enriched in enterohepatic tis-
sues, where it has diverse molecular and physiological
functions (Stein and Schoonjans 2015). LRH-1 has been
linked to cell proliferation and cancer development in
the intestine (Botrugno et al. 2004; Schoonjans et al.
2005) and pancreas (Petersen et al. 2010; Benod et al.
2011). In the liver, LRH-1 regulates variousmetabolic pro-
cesses, including bile acid synthesis (Mataki et al. 2007;
Lee et al. 2008; Out et al. 2011), glucose sensing and pro-
cessing (Oosterveer et al. 2012), and reverse cholesterol
transport (Stein et al. 2014). Although the function of
LRH-1 in the liver has been extensively studied, its com-
manding role in intermediary metabolism has never
been connected to tumorigenesis.
In this study, we report that LRH-1 promotes diethylni-
trosamine (DEN)-induced hepatocellular carcinoma
(HCC) by coordinating glutamine-induced anabolic me-
tabolism. We demonstrate that LRH-1 facilitates the
production of NADPH from glutamine by favoring a non-
canonical glutamine pathway that optimizes reductive
biosynthesis. Importantly, chronic and acute disruption
of LRH-1 also impairs glutamine-induced anaplerosis
and α-KG availability, ultimately leading to reduced
mTORC1 signaling. These results unveil an unexpected
role of LRH-1 in cancer intermediary metabolism with
broad-ranging implications on mTORC1 signaling.
Results and Discussion
Hepatic loss of LRH-1 prevents DEN-induced liver
carcinogenesis
To investigate the specific contribution of hepatic LRH-1
on HCC formation, we used the well-established DEN
method to induce liver cancer (Bakiri and Wagner 2013).
Liver-specific Lrh-1-deficient (Lrh-1hep−/−) and wild-type
control (Lrh-1hep+/+) mice were injected with DEN on
postnatal day 14. Tumor burden was assessed 6 mo
(mid-term) or 10 mo (long-term) after injection (Fig. 1A).
While long-term DEN-challenged Lrh-1hep+/+ littermates
developed multiple hepatic tumors, Lrh-1hep−/− mice
were strikingly protected (Fig. 1B,C). The robust reduction
of total tumor number and size was not caused by differ-
ences in DEN carcinogenicity as evidenced by the equal
accumulation of DNA adducts induced by DEN[Keywords: Hepatocellular carcinoma; cancer metabolism; nuclear
receptor NR5A2; mitochondria; anaplerosis; mTOR; NADPH]
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exposure in 14-d-oldLrh-1hep+/+ andLrh-1hep−/− livers (Fig.
1D; see the Supplemental Material for more details). Fur-
thermore, DEN moderately increased LRH-1 protein
abundance but did not affect its nuclear compartmentali-
zation (Fig. 1E). We then performed histological and
immunohistochemical analysis on the long-term DEN-
treated liver sections. H&E staining of Lrh-1hep−/− liver
sections demonstrated fewer microscopic tumor foci,
while BrdU and Ki67 staining confirmed reduced cell pro-
liferation in Lrh-1-deficient livers (Supplemental Fig.
S1A). Moreover, long-termDEN-treated Lrh-1hep−/− livers
were significantly lighter compared with Lrh-1hep+/+ liv-
ers, while the body weight did not differ between the
two genotypes (Supplemental Fig. S1B–D). Together,
these results indicate that LRH-1 is required for efficient
HCC induction and progression in response to DEN
treatment.
Hepatic loss of LRH-1 inhibits noncanonical glutamine
processing
LRH-1 coordinates intestinal cell renewal and tumor for-
mation through cross-talk with the β-catenin pathway
(Botrugno et al. 2004; Schoonjans et al. 2005). It is also re-
quired for hepatic endoplasmic reticu-
lum (ER) stress resolution through
transcriptional control of polo-like
kinase 3 (Plk3) and subsequent phos-
phorylation of activating transcription
factor 2 (ATF2) (Mamrosh et al. 2014).
To understand the robust tumor-sup-
pressive phenotype, we first assessed
the β-catenin pathway in mid-term
DEN-treated livers in which tumors
were not yet developed (Supplemental
Fig. S1E). In contrast to the findings in
intestinal crypts of germline Lrh-1+/−
mice (Botrugno et al. 2004), β-catenin
targets c-Myc, Ccnd1, and Ccne1
were not reduced in the unchallenged
(Supplemental Fig. S1F) or DEN-chal-
lenged (Supplemental Fig. S1G) Lrh-
1hep−/− livers. We also evaluated the
Plk3–ATF2 cascade in response to
acuteDEN exposure. Plk3mRNA lev-
els and ATF2 phosphorylation were
not induced by DEN (Supplemental
Fig. S1H; data not shown), indicat-
ing that, in our model, LRH-1 im-
pacts hepatocarcinogenesis via other
mechanisms. We then performed
microarray analysis to compare the
transcriptomes of mid-term DEN-
exposed Lrh-1hep+/+ and Lrh-1hep−/−
livers. As expected, gene set enrich-
ment analysis (GSEA) confirmed pre-
viously established functions and
target pathways of LRH-1, such as syn-
thesis of bile acids (Fig. 1F; Sup-
plemental Fig. S1I,J). Of interest,
metabolism of amino acid and deriva-
tives scored among the most signifi-
cantly enriched pathways (Fig. 1F;
Supplemental Fig. S1K). We next ana-
lyzed this gene set in more detail.
While transcripts of several proteasomal subunits were
down-regulated in Lrh-1hep−/− livers, a more striking re-
duction of several enzymes involved in glutamine catabo-
lism was observed (Fig. 1G). Glutamine plays an essential
role in tumor growth to support anaplerosis and reductive
biosynthesis (DeBerardinis et al. 2008). Several genes in-
volved in the processing of glutamine were reduced in
mid-term DEN-exposed Lrh-1hep−/− livers, including mi-
tochondrial glutaminase 2 (Gls2), cytosolic glutamate
oxaloacetate transaminase 1 (Got1), and mitochondrial
glutamate pyruvate transaminase 2 (Gpt2) (Fig. 1G,H).
This pathway is reminiscent of a noncanonical pathway
of glutamine breakdown that was earlier reported in hu-
man glioma (Wise et al. 2008) and pancreatic ductal ade-
nocarcinoma (PDAC) cells as an alternative mechanism
to support NADPH production via malic enzyme (Son
et al. 2013). Not only these genes but also malic enzyme
1 (Me1) were significantly blunted, as confirmed by quan-
titative RT–PCR (qRT–PCR) (Fig. 1I). Many cancer cells
typically rely on GLUD1 to fuel the TCA cycle through
repleting α-KG (DeBerardinis et al. 2008). Transcript lev-
els ofGlud1, however, remained unchanged upon hepatic
loss of function (LOF) of LRH-1 (Supplemental Fig. S1L).
Moreover, mRNA expression of Gls1, Got2, and TCA cy-
cle-related genes was not altered between the two
Figure 1. Hepatic Lrh-1-deficient mice are protected against DEN-induced HCC formation
and display reduced glutamine-dependent anaplerosis. (A) Experimental strategies of DEN ad-
ministration. (DOB) Date of birth. (B) Representative livers of 10-mo DEN-treated Lrh-1hep+/+
and Lrh-1hep−/−mice. (C ) Hepatic tumor number (left) and tumor size (right) in the correspond-
ing genotypes. (D) Hepatic O6-ethylguanine DNA adducts 6, 24, and 48 h after DEN injection
to 14-d-old Lrh-1hep+/+ and Lrh-1hep−/− mice. n = 5–6 per genotype and time point. (E) LRH-1
protein levels in cytosol and nucleus fractions of livers from untreated control (Ctrl), 6-mo
DEN-treated (MT), and 10-mo DEN-treated (LT) Lrh-1hep+/+ and Lrh-1hep−/− mice. (F ) Gene
set enrichment analysis (GSEA) demonstrates down-regulated pathways that were ranked by
normalized enrichment scores (NES) in livers of 6-mo DEN-treated Lrh-1hep−/− (n = 6) mice
compared with Lrh-1hep+/+ (n = 7) mice. Specific pathways are indicated. (G) Heat map display-
ing the core-enriched gene set “metabolism of amino acids and derivatives,” expressed in the
livers of the mice described in F. (H) Graphical representation of enzymes involved in gluta-
mine breakdown and metabolism. Enzymes highlighted in red are reduced in Lrh-1hep−/− livers,
as shown in I. (I ) Hepatic mRNA levels of glutaminase 2 (Gls2), glutamate oxaloacetate trans-
aminase 1 (Got1), glutamate pyruvate transaminase 2 (Gpt2), andmalic enzyme 1 (Me1) in liv-
ers of mice described in F. Data represent mean ± SEM. (∗) P < 0.05; (∗∗) P < 0.01; (∗∗∗) P < 0.001 by
two-tailed Student’s t-test.
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genotypes (Supplemental Fig. S1L,M). Col-
lectively, these data indicate that an alterna-
tive pathway involved in hepatic glutamine
processing is most likely compromised in
Lrh-1hep−/− mice.
LRH-1 regulates reductive biosynthesis
fueled by glutamine processing
We previously showed that LRH-1
coordinates glucose intermediary metabo-
lism via glucokinase (GCK) activation and
subsequent carbohydrate response ele-
ment-binding protein (ChREBP) nuclear
translocation (Oosterveer et al. 2012). Con-
sistent with this study, the ChREBP path-
way was significantly enriched between
both genotypes (Supplemental Fig. S2A,B).
Because Me1 is a known ChREBP target
gene (Iizuka et al. 2004; Chambers et al.
2013), we first analyzed whether the reduc-
tion of our candidate genes (Fig. 1I) results
from impaired GCK–ChREBP signaling.
GCK reconstitution in Lrh-1hep−/− livers re-
stored Chrebpβ and Me1 (Fig. 2A), but not
Gls2,Got1, orGpt2 expression (Supplemen-
tal Fig. S2C), indicating that LRH-1 regu-
lates only Me1 via the GCK–ChREBP axis.
In parallel to the reduced Me1 expression,
NADPH/NADP+ levels were significantly
reduced in unchallenged (Fig. 2B) or DEN-
challenged (Fig. 2C) Lrh-1hep−/− livers and
was accompanied by a corresponding reduc-
tion of the GSH/GSSG ratio in DEN-treated
livers (Fig. 2D). Although Me1 was readily
rescued upon GCK reconstitution (Fig. 2A),
normalization of NADPH/NADP+ levels
was still incomplete (Fig. 2B), supporting
the notion that the generation of NADPH
from glutamine is also attenuated in Lrh-
1hep−/− livers.
We next investigated the molecular mechanism
through which LRH-1 regulates glutamine metabolism.
Overexpression of LRH-1 in mouse hepatoma Hepa 1.6
cells resulted in an increase of GLS2 transcripts and pro-
tein, while Got1 and Gpt2 transcripts were unchanged
(Fig. 2E,F). Conversely, siRNA-mediated silencing of
LRH-1 exclusively reduced the expression of GLS2
mRNA and protein (Fig. 2G,H). In Lrh-1hep−/− mice, re-
duced hepaticGls2mRNA expression (Fig. 1H) translated
into lower GLS2 protein levels (Fig. 2I). Of interest, Gls2
is highly expressed in the liver compared with Gls1 (Sup-
plemental Fig. S2D). GLS2 deaminatesmitochondrial glu-
tamine, thus controlling a major anaplerotic step for
hepatic glutamine utilization (Hensley et al. 2013). We
then asked whether Gls2 is subjected to direct transcrip-
tional regulation by LRH-1. Analysis of a genome-wide he-
patic LRH-1 ChIP-seq (chromatin immunoprecipitation
[ChIP] combined with high-throughput sequencing) data
set (Chong et al. 2012) revealed LRH-1 recruitment at
the Gls2 promoter (Fig. 2J), and computational analysis
identified five putative LRH-1 response elements within
the Gls2 promoter under the LRH-1 ChIP-seq peak (Fig.
2K). Site-specific ChIP assays using DNA from mid-term
DEN-treated Lrh-1hep+/+ and Lrh-1hep−/− livers revealed
LRH-1 recruitment to putative binding sites 1, 2, and 3
(Fig. 2L). Mutation of these binding sites in mouse Gls2-
luciferase reporter constructs furthermapped site 3,which
is conserved in the human Gls2 promoter (Supplemental
Fig. S2E), as the major site that confers LRH-1 responsive-
ness (Fig. 2M). Accordingly, silencing of LRH-1 in human
hepatoma HepG2 cells also led to a significant reduction
of Gls2 transcripts (Supplemental Fig. S2F).
LRH-1 regulates GLS2 to promote glutamine-induced
anaplerosis
Given the marked reduction of GLS2 in Lrh-1hep−/−mice,
we hypothesized that hepatic loss of LRH-1 blunts
the conversion of glutamine to glutamate. To test the
flux throughGLS2 in vivo, we performed 13Cnuclearmag-
netic resonance (13CMR) spectroscopymeasurements fol-
lowinghyperpolarized [5-13C]glutamine injection (Cabella
et al. 2013;Cheng et al. 2013). [5-13C]glutaminewashyper-
polarized using dissolution dynamic nuclear polarization
(DNP) and rapidly injected into DEN-treated Lrh-1hep−/−
and Lrh-1hep+/+ mice followed by real-time recording
of its conversion to [5-13C]glutamate (Fig. 3A,B). As ex-
pected, Lrh-1hep−/− showed a strong decrease in hepatic
Figure 2. Gls2 is a direct transcriptional target of LRH-1. (A,B) Hepatic mRNA levels of
Gck, Chrebpβ, andMe1 (A) and NADPH/NADP+ levels (B) in control virus-infected Lrh-
1hep+/+ and Lrh-1hep−/−mice and AAV8-GCK virus-infected Lrh-1hep−/−mice. n = 4–5 per
group. Data represent mean ± SEM. (∗) P < 0.05 versus Lrh-1hep+/+; (#) P < 0.05 versus Lrh-
1hep−/− by one-way ANOVA and Tukey’s post-hoc test. (C,D) Relative NADPH/NADP+
(C ) and GSH/GSSG (D) levels in livers of 6-mo DEN-treated Lrh-1hep+/+ (n = 7) and Lrh-
1hep−/− (n = 6) mice. (E,F ) mRNA levels of Gls2, Got1, and Gpt2 (E) and protein levels of
GLS2 (F ) in Hepa 1.6 cells transfected with control or Lrh-1 expression plasmids. n = 3
per group. (G,H) mRNA levels of Gls2, Got1, and Gpt2 (G) and protein levels of GLS2
(H) inHepa 1.6 cells transfectedwith scrambled or Lrh-1 targeted siRNAs. n = 3 per group.
Data represent mean ± SEM. (∗∗) P < 0.01; (∗∗∗) P < 0.001 by two-tailed Student’s t-test. (I )
Hepatic protein levels of GLS2 inmice described inC. (J) University of California at Santa
Cruz (UCSC) genomebrowser (mm9) viewdisplaying the occupancyofmouseGls2by IgG
and LRH-1 (Chong et al. 2012). (K ) Schematic representation of the five putative LRH-1
response elements in the proximal mouseGls2 promoter. (L) ChIP-qPCR (chromatin im-
munoprecipitation [ChIP] combined with qPCR) assay to evaluate the relative LRH-1
binding to the mouseGls2 promoter. Amplified regions (a, b and c) are depicted in Figure
1K. (M ) Luciferase activities in HEK293A cells after cotransfection of a Lrh-1 expression
vector and with empty luciferase reporter (pGL4) and long or short Gls2 promoter con-
structs with or without the indicated mutations. Data represent mean ± SEM. (∗∗∗) P <
0.001 versus empty reporter (pGL4); (#) P < 0.05 versus long Gls2 promoter construct by
one-way ANOVA and Tukey’s post-hoc test.
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[5-13C]glutamate content compared with
Lrh-1hep+/+mice (Fig. 3C). Unlike the expres-
sion levels of glutamine transporters Slc1a5
and Slc7a5, which were unchanged (Supple-
mental Fig. S3A), hepatic α-KG levels were
diminished in Lrh-1hep−/−mice (Fig. 3D), in-
dicating that LRH-1 LOF may attenuate
glutamine-fueled anaplerosis. To further ex-
plore the direct roles of LRH-1 and GLS2 in
maintaining glutaminolysis and intracellu-
larα-KGpools,weexamined the effect of glu-
taminemetabolismon α-KG levels.Hepa 1.6
cells were starved of glutamine for 6 h, and
removal of glutamine significantly reduced
the intracellular levels of α-KG (Supplemen-
tal Fig. S3B), demonstrating that glutamine
sustains glutaminolysis. We then acutely
modulated LRH-1 or GLS2 expression in
Hepa 1.6 cells. In line with the reduced
α-KG abundance in Lrh-1hep−/− livers, over-
expression of LRH-1 or GLS2 increased,
while siRNA-mediated silencing of LRH-1
or GLS2 decreased, α-KG levels in Hepa 1.6
cells (Fig. 3E–H). Together, these results
demonstrate that LRH-1 promotes gluta-
mine-induced anaplerosis via the induction
of GLS2.
LRH-1 modulates the mTORC1 pathway
in an α-KG-dependent manner
Glutamine is metabolized through glutami-
nolysis to produce α-KG. Previous studies showed that in-
creased glutamine (Duran et al. 2012; Bar-Peled and
Sabatini 2014) or α-KG (Duran et al. 2012) availability
stimulates the mTORC1 signaling pathway. Of note, a ro-
bust reduction of mTORC1 activation was observed in
Lrh-1hep−/− livers, as evidencedby thedecreasedphosphor-
ylationof 4EBP1andS6K (Fig. 3I).We then investigated the
importance of glutamine in the activation of mTORC1 in
Hepa 1.6 cells. Depletion of glutamine for 6 h reduced α-
KG levels (Supplemental Fig. S3B) and inhibitedmTORC1
activity (Supplemental Fig. S3C).Moreover, supplementa-
tion of a cell-permeable α-KG analog, dimethyl-KG (DM-
KG), restored the activation of mTORC1 signaling upon
glutaminedeprivation (Supplemental Fig. S3D), indicating
that intracellular glutamine and its derived α-KG are es-
sential to stimulate mTORC1. Based on these results, we
overexpressed LRH-1 or GLS2 in Hepa 1.6 cells. In both
settings, mTORC1 activity was induced in the presence
of glutamine (Fig. 3J,K). These effects were reversed upon
glutamine starvation (Supplemental Fig. S3E,F). Further-
more, RNAi-mediated suppression of LRH-1 or GLS2 in-
terfered with phosphorylation of 4EBP1 and S6K in the
presence of glutamine, while addition of DM-KG or over-
expression of GLS2 or LRH-1, respectively, rescued
mTORC1 activities (Fig. 3L,M; Supplemental Fig. S3G,
H). These datahence suggest that theLRH-1–GLS2axis in-
creases α-KG levels and consequently activatesmTORC1.
The LRH-1–GLS2 axis promotes cell proliferation
Activation of mTORC1 inhibits autophagy (Kim et al.
2011), activates protein translation (Ma and Blenis 2009),
and promotes cell growth (Schmelzle and Hall 2000). To
investigate the importance of the LRH-1–GLS2–mTORC1
pathway, we first assessed autophagy in mid-term DEN-
treated livers. As expected, disruption of LRH-1 induced
autophagy, as evidenced by reduced phosphorylation of
ULK-1 at Ser757, blunted P62, and increased LC3-II levels
(Supplemental Fig. S4A). Silencing of LRH-1 or GLS2 de-
creased global protein translation asmeasured by incorpo-
ration of 35S-labelledmethionine inHepa 1.6 cells (Fig. 4A,
B), while their overexpression enhanced translation (Sup-
plemental Fig. S4B,C).We thenevaluated the linkbetween
LRH-1, α-KG, and cell proliferation.As expected, LRH-1 or
GLS2 overexpression promoted cell proliferation, while
additional glutamine deprivation prevented the increase
in cell proliferation (Fig. 4C,D). Conversely, inhibition
of glutaminolysis by LRH-1 or GLS2 silencing inhibited
cell proliferation, while overexpression of LRH-1 or
GLS2 rescued this effect (Supplemental Fig. S4D,E).More-
over, diminished cell proliferation upon LRH-1 or GLS2
suppression could also be rescued by addition of DM-KG
(Fig. 4E,F), indicating that the LRH-1–GLS2 axis activates
cell proliferation in an α-KG-dependent manner. It has
been shown that GLS2-catalyzed deamination of glu-
tamine is also essential for the control of intracellular
reactive oxygen species (ROS) levels (Hu et al. 2010). Sup-
plementation with the antioxidant N-acetyl-cysteine
(NAC), however, could not rescue the inhibited cell pro-
liferation upon LRH-1 or GLS2 silencing in Hepa 1.6
cells (Supplemental Fig. S4F,G), suggesting that reduced
mTORC1 signaling rather than induced oxidative stress
accounts for the reduction in cell proliferation. Further-
more, Hepa 1.6 cells silenced for LRH-1 or GLS2 induced
significantly less tumor growth after propagation in athy-
mic nude mice (Fig. 4G). Taken together, these findings
Figure 3. LRH-1 controls glutamine-induced anaplerosis and regulates mTORC1 activ-
ity. (A) GLS2-mediated biochemical reaction with hyperpolarized [5-13C]glutamine. Red
dots indicate the labelling of C5. (B–D) Representative in vivo 13C MR spectra showing
hyperpolarized [5-13C]glutamate productionwith the by-product signal of hyperpolarized
[5-13C]pyroglutamate (B), the mean signal intensity of the hyperpolarized [5-13C]gluta-
mate formed via glutaminase (C ), and intracellular α-KG levels (D) in the livers of
DEN-treated Lrh-1hep+/+ and Lrh-1hep−/− mice. (E–H) Intracellular α-KG levels in Hepa
1.6 cells transfected with either control or Lrh-1 expression plasmids (n = 3 per group
(E) or scrambled or Lrh-1 targeted siRNAs (n = 3 per group) (F ), transduced with either
AdGFP or AdGLS2 viruses (n = 3 per group) (G), or transfectedwith scrambled orGls2 tar-
geted siRNAs (n = 3 per group) (H). (I ) Phosphorylation states of S6K and 4EBP1 in the liv-
ers of mice described in B. (J–M ) Phosphorylation states of S6K and 4EBP1 in Hepa 1.6
cells transfected as in E (J), transduced as in G (K ), transfected as in F (L), or transfected
as in H (M ) with or without dimethyl-KG (DM-KG) supplementation (L,M ). Data repre-
sent mean ± SEM. (∗) P < 0.05; (∗∗) P < 0.01; (∗∗∗) P < 0.001 by two-tailed Student’s t-test.
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highlight that LRH-1 promotes cell proliferation through
glutaminolysis and mTORC1 signaling.
In conclusion, our study assigns a critical role to LRH-1
in hepatic fuel metabolism with a striking impact on he-
patic tumorigenesis. Unlike the role of LRH-1 in the intes-
tine and pancreas, the oncogenic potential of hepatic
LRH-1 is independent from the β-catenin/Wnt signaling
pathway and is instead driven by the regulation of specific
gene programs involved in mitochondrial glutamine ca-
tabolism (Fig. 4H). The enhanced mTORC1 signaling
upon LRH-1-induced glutaminolysis indicates that the ef-
fect of LRH-1 on glutamine processing also impinges on
established kinases in cell growth and cancer, thereby fur-
ther amplifying the overall growth-stimulating effect.
These observations, together with our previous findings
linking LRH-1 to glucose-dependent fatty acid biosynthe-
sis via ChREBP activation (Oosterveer et al. 2012), support
the notion that LRH-1 confers a protumorigenic status to
hepatocytes by promoting themetabolism of the principal
fuel substrates of cancer cells. Further studies arewarrant-
ed to fully understand its role in human HCC and explore
its potential as a drug target.
Materials and methods
Animal studies
Hepatocyte-specific LRH-1 knockout (Lrh-1hep−/−) and wild-type
(Lrh-1hep+/+) mice were previously reported (Oosterveer et al. 2012). Con-
genic neonatal mice at 14 d old were intraperitoneally injected with
DEN at a dose of 25 mg per kilogram of body weight to initiate tumor for-
mation. Six months (mid-term DEN) or 10 mo (long-term DEN) after in-
jection, mice were sacrificed, and liver tissue was collected. The
experiments with the AAV8 viruses have been described previously (Oos-
terveer et al. 2012). Five-week-old male BALB/c nu/nu mice were pur-
chased from Charles River and maintained in the animal facilities. All
animal procedures were approved by the Swiss authorities (Canton of
Vaud, animal protocol IDs 2375 and 2768) and performed in accordance
with our institutional guidelines.
ChIP
ChIP analysiswas performed as described previouslywithminormodifica-
tions (Stein et al. 2014). DNAwas purified using the PCR clean-up extrac-
tion kit (Macherey-Nagel), after which qRT-PCR was performed as
described previously (Mataki et al. 2007). Data were normalized to the in-
put [fold differences = 2−(Ct sample−Ct input)]. ChIP primer sequences are list-
ed in Supplemental Table 1.
Measurements of metabolites
For NADPH/NADP+ and GSH/GSSG ratios, liver biopsies were extracted
with 70% ethanol, and biomass was separated by centrifugation at 4000
rpm for 10min. Liquid extracts were then dried by vacuum centrifugation,
resuspended in 10 µL of water per milligram of wet weight, and analyzed
by targeted liquid chromatography-tandem mass spectrometry on a
ThermoQuantumUltra instrument equipped with aWaters Acquity ultra
high performance liquid chromatographer (UPLC). Intracellular α-KG lev-
els were determined using commercial kits (Abcam, ab83431) according to
the manufacturer’s instructions.
In vivo hyperpolarized 13C MR measurements
DEN-treated Lrh-1hep+/+ and Lrh-1hep−/− mice were anesthetized with
∼1.8% isoflurane, 0.5% O2, and 0.5% air. A 750-µL bolus containing a
dose of 0.57 mmol/kg ± 0.02 mmol/kg hyperpolarized [5-13C]glutamine
was administered in 9 sec. A series of 30°C BIR4 adiabatic RF excitation
pulses were applied using a custom-built dual 1H/13C probe (two 1H sur-
face coils placed in quadrature on top of a 13C single-loop surface coil)
placed under the animal on the shaved skin located above the mouse’s
liver. In vivo 13C MR measurements were respiratory-gated and triggered
with simulated cardiac signal with a repetition time of 1 sec. Acquisi-
tions were performed with an INOVA spectrometer (Varian/Magnex).
The peak integrals were obtained from summed spectra analyzed using
VNMRJ.
Allograft tumor study
Hepa 1.6 cells suspended in phosphate-buffered salinewere injected subcu-
taneously into the left flanks of nude mice (4 × 106 cells per flank). The di-
ameters of the tumors were measured every 3 d, and tumor volumes (V)
were calculated using the formula V = L×W2/2, where L is length, and W
is width.
Statistical analysis
Data represent mean ± SEM. Comparison of differences between two
groups was assessed using two-tailed Student’s t-tests. Multiple group
comparisons were assessed by one-way ANOVA and Tukey’s post-hoc
test. Differences under P < 0.05 were considered statistically significant
(P < 0.05 [∗], P < 0.01 [∗∗], and P < 0.001 [∗∗∗]).
More experimental Materials and Methods are included in the Supple-
mental Material.
Figure 4. The LRH-1–GLS2 axis promotes protein translation and
cell proliferation. (A,B) Global protein synthesis measured by 35S-la-
belledmethionine incorporation inHepa 1.6 cells transfectedwith ei-
ther scrambled or Lrh-1 targeted siRNAs (n = 3 per group) (A) or
scrambled or Gls2 targeted siRNAs (n = 3 per group) (B). Relative 35S
methionine signals were normalized to Tubulin. Data represent
mean ± SEM. (∗) P < 0.05; (∗∗) P < 0.01 by two-tailed Student’s t-test.
(C–F ) Relative viable cells and representative Crystal Violet staining
images of Hepa 1.6 cells transfected with either control or Lrh-1 ex-
pression plasmids (n = 3 per group) (C ) or transduced with either
AdGFP or AdGLS2 viruses (n = 3 per group) (D) with or without gluta-
mine deprivation or scrambled or Lrh-1 targeted siRNAs (n = 3 per
group) (E) or scrambled or Gls2 targeted siRNAs (n = 3 per group) (F )
with or without DM-KG supplementation. Data represent mean ±
SEM. (∗) P < 0.05; (∗∗∗) P < 0.001 by one-way ANOVA and Tukey’s
post-hoc test. (G) Comparison of tumor growth and volume of mice
subcutaneously injected with Hepa 1.6 cells that were transduced
with scrambled, LRH-1 targeted, or GLS2 targeted shRNA. n = 6 per
group. (H) Graphical summary illustrating how LRH-1 promotes glu-
tamine-induced anaplerosis and reductive biosynthesis in hepatic
cancer cells. Enzymes highlighted in red are reduced in Lrh-1hep−/−
livers, and an asterisk indicates indirect regulation by LRH-1.
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